Academic literature on the topic 'Glucagon-like peptide analogues'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glucagon-like peptide analogues.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Glucagon-like peptide analogues"
Zhang, Yifan, and Wengen Chen. "Radiolabeled glucagon-like peptide-1 analogues." Nuclear Medicine Communications 33, no. 3 (March 2012): 223–27. http://dx.doi.org/10.1097/mnm.0b013e32834e7f47.
Full textGupta, Vishal. "Glucagon-like peptide-1 analogues: An overview." Indian Journal of Endocrinology and Metabolism 17, no. 3 (2013): 413. http://dx.doi.org/10.4103/2230-8210.111625.
Full textNilsson, Peter M. "Hemodynamic effects by glucagon-like peptide-1 receptor analogues." Journal of Hypertension 35, no. 5 (May 2017): 953–54. http://dx.doi.org/10.1097/hjh.0000000000001315.
Full textWilding, John P. H., and Kevin Hardy. "Glucagon-like peptide-1 analogues for type 2 diabetes." BMJ 342 (2011): d410. http://dx.doi.org/10.1136/bmj.d410.
Full textChun, Hyun-Ji, and Hyuk-Sang Kwon. "Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues." Journal of Korean Diabetes 14, no. 3 (2013): 125. http://dx.doi.org/10.4093/jkd.2013.14.3.125.
Full textGallwitz, Baptist. "Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus." Drugs 71, no. 13 (September 2011): 1675–88. http://dx.doi.org/10.2165/11592810-000000000-00000.
Full textDharmaraj, B. "A brief review on newer Glucagon like Peptide-1 analogues." International Journal of Preclinical and Clinical Research 1, no. 1 (December 21, 2020): 26–34. http://dx.doi.org/10.51131/ijpccr/v1i1.7.
Full textIacobellis, Gianluca. "Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?" Polish Archives of Internal Medicine 131, no. 3 (March 30, 2021): 224–25. http://dx.doi.org/10.20452/pamw.15904.
Full textJuul Holst, Jens. "Glucagon-like Peptide-1, A Gastrointestinal Hormone with a Pharmaceutical Potential." Current Medicinal Chemistry 6, no. 11 (November 1999): 1005–17. http://dx.doi.org/10.2174/092986730611220401163238.
Full textWilliams, David M., Matthew Staff, Stephen C. Bain, and Thinzar Min. "Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity." Endocrinology 18, no. 1 (2022): 43. http://dx.doi.org/10.17925/ee.2022.18.1.43.
Full textDissertations / Theses on the topic "Glucagon-like peptide analogues"
Green, Brian Desmond. "Amino-terminally modified analogues of glucagon-like peptide-1 (7-36) amide : activity and antidiabetic potential." Thesis, University of Ulster, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.398986.
Full textFonseca, Filipa Ribeiro da. "Establishment of bioengineered glucose-responsive nanoparticles for type 2 diabetes mellitus therapy." Master's thesis, Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier, 2019. http://hdl.handle.net/10362/130074.
Full text"Type 2 diabetes mellitus (T2DM) is one of the biggest health problems in the world. Glucagon like peptide-1, an endogenous gastrointestinal incretin hormone that stimulates insulin secretion, is considered an attractive therapeutic agent for T2DM treatment. Nevertheless, its short half-life has led to the development of longer half-life GLP-1 analogues, as exenatide. Still, current dosage forms for exenatide delivery are not exempt of shortcomings. Nanotechnology-based systems may offer several advantages over conventional dosage forms for drug delivery.(...)"
N/A
Bellman, Susan Marie. "The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review and meta-analysis." Thesis, 2016. http://hdl.handle.net/2440/99884.
Full textThesis (M.Clin.Sc.) -- University of Adelaide, Joanna Briggs Institute, 2016.
Araújo, Ana Francisca Lopes Correia de. "Glucagon-like peptide-1 and glucagon-like peptide-1 analogs nanotechnology-based systems for prevention and therapy of diabetes." Doctoral thesis, 2017. https://repositorio-aberto.up.pt/handle/10216/103191.
Full textAraújo, Ana Francisca Lopes Correia de. "Glucagon-like peptide-1 and glucagon-like peptide-1 analogs nanotechnology-based systems for prevention and therapy of diabetes." Tese, 2017. https://repositorio-aberto.up.pt/handle/10216/103191.
Full textLiu, Hsien-Yueh, and 劉獻岳. "Exendin-4, a glucagon-like peptide-1 analogue, improves Listeria monocytogenes infection in diabetic db/db mice." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/89597295148737323856.
Full text國立中興大學
獸醫學系暨研究所
103
This diabetes mellitus has similar characteristics in both humans and animals. The incidence of this disease is increasing among companion animals. Diabetes is frequently identified as an independent risk factor for infections associated with increased mortality. In this study, homozygous diabetic (db/db) mice were infected with Listeria monocytogenes and then treated with the diabetic treatment drug Exendin-4, a glucagon-like peptide 1 analogue. In aged db/db mice, decreased CD11b+ macrophage populations with higher lipid content and lower phagocytic activity were observed. Exendin-4 lowered high lipid levels and enhanced phagocytosis in macrophages from db/db mice infected with L. monocytogenes. Exendin-4 also ameliorated obesity and hyperglycemia, and improved ex vivo bacteria clearance by macrophages in the diabetic animals. Liver histology examined during L. monocytogenes infection indicated that abscess formation was much milder in Exendin-4 treated db/db mice than in the control animals. Moreover, the expression of ATP binding cassette transporter 1, a sterol transporter, in the macrophages isolated from the Exendin-4 treated db/db mice was higher than the untreated group. Overall, our results indicated that Exendin-4 reduces the risk of infection in diabetic animals by modulating the interaction between intracellular lipids and phagocytic ability of macrophages
Books on the topic "Glucagon-like peptide analogues"
Green, Brian Desmond. Amino-terminally modified analogues of glucagon-like Peptide-1(7-36)Amide: Activity and antidiabetic potential. [S.l: The Author], 2003.
Find full textBook chapters on the topic "Glucagon-like peptide analogues"
Dong, Jesse Z., Yeelana Shen, John E. Taylor, Michael Culler, Chee-Wai Woon, Barry Morgan, Steve Skinner, and Jacques-Pierre Moreau. "Glucagon-Like Peptide-1 Analogs with Significantly Improved in vivo Activity." In Peptides: The Wave of the Future, 670–71. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_312.
Full textLi, Hongjian, Cindy X. Zhou, and Zhengding Su. "Protease-resistant glucagon like peptide-1 analogs with long-term anti-diabetes type 2 activity." In Advances in Experimental Medicine and Biology, 475–76. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-73657-0_204.
Full textKumar, Ajay. "Glucagon-like Peptide-1 Analogues." In Diabetology: Type 2 Diabetes Mellitus, 87. Jaypee Brothers Medical Publishers (P) Ltd., 2014. http://dx.doi.org/10.5005/jp/books/12165_8.
Full textKumar, Ajay. "Chapter-08 Glucagon-like Peptide-1 Analogues." In Challenging and Rare Cases in Urology, 87–104. Jaypee Brothers Medical Publishers (P) Ltd., 2014. http://dx.doi.org/10.5005/jp/books/12153_8.
Full textMiddleton, Stephen J., Simon M. Gabe, and Raymond J. Playford. "Effects of massive bowel resection." In Oxford Textbook of Medicine, edited by Jack Satsangi, 2911–16. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0304.
Full textDeshpande, Neeta, and Pooja Kulkarni. "Glucagon-like Peptide-1 Analogs for Obesity Management." In RSSDI Diabetes Update 2016, 371. Jaypee Brothers Medical Publishers (P) Ltd., 2017. http://dx.doi.org/10.5005/jp/books/13026_68.
Full textDiz-Chaves, Yolanda, Salvador Herrera-Pérez, Lucas C. González-Matías, and Federico Mallo. "Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus." In Vitamins and Hormones. Elsevier, 2022. http://dx.doi.org/10.1016/bs.vh.2021.12.005.
Full textPei, Zhe, Kuo-Chieh Lee, Amber Khan, and Hoau-Yan Wang. "Brain Insulin Resistance, Nitric Oxide and Alzheimer’s Disease Pathology." In The Role of Nitric Oxide in Type 2 Diabetes, 238–59. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815079814122010014.
Full textConference papers on the topic "Glucagon-like peptide analogues"
Abudalo, Rawan, Kevin Edgar, Karla O’Neill, David Grieve, and Brian Green. "146 Glucagon-like peptide-1 analogues exert differential in vitro actions on macrophages and cardiac fibroblasts in experimental diabetes." In British Cardiovascular Society Annual Conference ‘High Performing Teams’, 4–6 June 2018, Manchester, UK. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-bcs.142.
Full textReports on the topic "Glucagon-like peptide analogues"
Luan, Sisi, Wenke Cheng, Chenglong Wang, Hongjian Gong, and Jianbo Zhou. Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0015.
Full text